Evicenter
Repatha (evolocumab) in Cardiovascular event risk reduction
Manufacturer
Amgen Inc.
Prescribing information
Repatha (opens in a new tab)
Questions
14
Last updated

All questions

Guidelines: Repatha (evolocumab) in cardiovascular event risk reduction

2 questions · 1 source

Guidelines

Repatha and LDL-C goals: what does the 2026 ACC/AHA guideline say?

Note: These are LDL-C goals by patient group from Amgen's summary of the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia (Blumenthal et al., JACC, published online March 2026) on the Repatha HCP site. They apply to LDL-C lowering therapy in general and do not name Repatha. Each list on the page ends in a See More control.

Repatha: when does the 2026 ACC/AHA guideline recommend adding a PCSK9 inhibitor?

Note: These are recommendations for PCSK9 inhibitor monoclonal antibodies (PCSK9i mAbs) as a class, in Amgen's summary of the 2026 ACC/AHA/Multisociety Guideline on the Management of Dyslipidemia (Blumenthal et al., JACC, published online March 2026) on the Repatha HCP site. The phrase "like evolocumab" and the description of the key updates are Amgen's wording.